Full-Time
Claims Specialist
Resilience
1,001-5,000 employees
Cyber insurance paired with risk-quantifying SaaS
Compensation Overview
$100k - $130k/yr
Remote in USA
Remote
 Legal & Compliance (1) |
|---|
Get referred to Resilience
See people who can refer or advise you
- 2–4 years of experience in claims handling, claims advocacy, or cyber insurance coverage.
- Ability to evaluate primary and excess coverage, navigate increasingly complex cases, and communicate clearly with insureds, brokers, vendors, and underwriters.
- Expertise in handling third-party claims, particularly in Technology Errors & Omissions and Miscellaneous Professional Lines.
- Established connections within the cyber broking community, incident response, or cybersecurity sectors.
- Ability to work cross-functionally across security, technology, and underwriting departments in a fast-paced environment.
- Own the day-to-day investigation and management of Cyber, Technology Errors & Omissions, and Miscellaneous Professional Lines claims.
- Take ownership of a dedicated claims portfolio.
- Conduct claim investigations and manage negotiations.
- Apply insurance-contract expertise to recommend accurate claim reserves.
- Collaborate with internal security and technology teams to provide policyholders with proactive incident response and preventative services.
- Manage external service providers during incidents to reduce losses.
- Maintain meticulous claim-file documentation.
- Establish a continuous data and analytics feedback loop with the Underwriting team to refine risk selection.
Resilience provides cyber insurance to mid-market and large enterprises and licenses the Resilience Solution, a SaaS platform that translates a company’s security posture into a financially oriented action plan used for underwriting and risk management. The platform quantifies technology controls, estimates ROI of security investments, and informs insurance pricing. It runs a risk operations center with continuous threat intelligence and in-house claims handling, emphasizing third-party risk. Goal: move beyond risk transfer by actively improving client security and reducing losses across sectors such as manufacturing, agriculture, and healthcare.
Company Size
1,001-5,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$3.2B
Headquarters
San Diego, California
Founded
2020
Get referred to Resilience
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 30, 2026 Lilly committed $750 million for KwikPen expansion and 400 jobs.
- October 2025 Oak Hill financed up to $825 million, including $525 million initial funding.
- June 18, 2026 Blue Ash headquarters move adds $100 million and 200 jobs.
What critics are saying
- Six sites wound down in 2025 after overbuilt capacity outpaced industry demand.
- Alachua, Fremont, San Diego, Allston, Bedford, and Marlborough closures expose execution failure.
- Dependence on Lilly and Ohio execution creates concentration risk if KwikPen ramps slip in 2027.
What makes Resilience unique
- Resilience pairs sterile manufacturing with packaging, regulatory, and supply-chain control in one network.
- Lilly partnership since 2023 produced over 150 million U.S. doses by July 2026.
- Blue Ash headquarters and Cincinnati plants anchor a concentrated, high-throughput sterile platform.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Company Match
Unlimited Paid Time Off
Paid Holidays
Family Planning Benefits
Fertility Treatment Support
Tuition Reimbursement
Performance Bonus
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↑ 0%Lilly and Resilience invest $750M in diabetes and obesity drug device supply. July 31, 2026 | The investment will expand Resilience's U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines. Eli Lilly is expanding its partnership with service provider Resilience, with the pair committing $750 million to U.S. drug manufacturing capacity. The partners are using the cash to bolster Resilience's operations in the Cincinnati region. Through the investment, Resilience will significantly increase U.S. production of Lilly's KwikPen injectable device for diabetes and obesity medicines. The contract development and manufacturing organization (CDMO) is preparing the site for expansion with the aim of starting full operations early next year. In February, Lilly won FDA approval for Zepbound in a multidose KwikPen device. The product includes four doses of the GLP-1/GIP receptor agonist, providing a month of treatment for obesity or overweight in one device. Despite seeing some regain, patients in two trials maintained most of their weight loss after switching to either Foundayo or lower-dose Zepbound from other injectable incretin therapies. May 13, 2026 Resilience expects the KwikPen capacity expansion to create at least 400 jobs in the Cincinnati area. The addition of the new roles will bring the number of jobs created by Resilience in Ohio - where the CDMO has two sites around Cincinnati - up to 1,400. Resilience also has plants in Philadelphia and Toronto. The spend on the Ohio site continues Resilience's rapid rise. Launched in 2020 with more than $800 million from backers including Arch Venture Partners and 8VC, the CDMO went on to form pacts with companies including AstraZeneca, Sanofi and Takeda while raising almost $2.5 billion across two financing rounds, a debt deal and a loan from the U.S. Department of Defense. Resilience has used the money to add manufacturing capacity. The CDMO expanded a facility in West Chester, Ohio, in 2023; invested $225 million in a Cincinnati plant in 2024; and grew at two Ohio locations in 2025. In June, Resilience moved its corporate headquarters from San Diego to Blue Ash, Ohio, a northern suburb of Cincinnati. The company has partnered with JobsOhio to help staff the sites. The CDMO began working with Lilly in 2023. Resilience's archives lack a press release naming Lilly as a partner in 2023, although that year the CDMO did disclose a 10-year biomanufacturing alliance with an unnamed "leading pharmaceutical company." At the time, Resilience predicted the deal would support record revenues. Resilience has made more than 150 million doses of medicines for Lilly. Eli Lilly's latest manufacturing expansion will support production of obesity blockbusters and next-gen assets, while the new Lilly Lebanon Advanced Therapies site will take experimental genetic medicines from research to commercialization. May 8, 2026
Resilience and Lilly to increase US medicines production with $750m investment. The investment will support Resilience's advanced manufacturing operations in Cincinnati. Resilience and Eli Lilly and Company have expanded their partnership with a joint $750m investment to increase the production of Lilly's KwikPen injectable device in Ohio, aiming to strengthen the supply of diabetes and obesity medicines in the US. The investment will support the expansion of Resilience's advanced manufacturing operations in the Cincinnati region and create at least 400 new jobs. With this initiative, the total number of jobs generated by Resilience across its Ohio sites will exceed 1,400. Preparation for the site expansion has commenced, and complete operations are projected to begin in early 2027. The expanded collaboration builds upon a strategic partnership between the two firms first formed in 2023. This initiative is in response to growing patient demand for injectable treatments for diabetes and obesity in the US. Resilience president and CEO William Marth said: "Hospital Management is proud of what Hospital Management has built together with Lilly and this new expansion as Hospital Management scale production of complex medicines in Ohio. "Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the US, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Lilly executive vice-president and manufacturing operations president Edgardo Hernandez said: "As demand for our medicines continues to increase, scaling complex manufacturing programmes requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time." The partnership has so far resulted in the production of more than 150 million doses of medicines for US patients in vial and pre-filled syringe formats. Resilience operates two facilities in the region, employing nearly 1,000 staff across various functions. The location in Blue Ash, Ohio, was recently established as Resilience's global headquarters. The company's partnerships with REDI Cincinnati, JobsOhio, and Ohio Life Sciences have also supported workforce development efforts in the Cincinnati area. Prior to this, Eli Lilly and Company entered an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Give your business an edge with its leading industry insights.
Tech investors are doubling down on the infrastructure underpinning today’s AI boom – from satellites in orbit to power-hungry data centers on Earth. The day’s largest deals span space tech, clean energy and AI-infused enterprise platforms, signaling where capital is flowing: into hardware-heavy, mission-critical fields. Satcom manufacturer K2 Space ($500M Series D) and thermal-battery startup Antora Energy ($550M
Resilience, Lilly invest $750M in pharma, KwikPen manufacturing. Resilience announced today that it expanded its strategic partnership with Eli Lilly (NYSE:LLY) to increase medicine production in the U.S. The Cincinnati-based CDMO and the pharmaceutical giant first struck a partnership in 2023. Now, with $750 million invested, the companies are expanding Resilience's advanced pharmaceutical manufacturing operations in Ohio. Now, Resilience's production in that region includes the Lilly KwikPen injectable device for delivering GLP-1 therapies for diabetes and obesity. Adding KwikPen production also creates at least 400 new high-skilled jobs. That brings the total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Resilience and Lilly have preparation underway for the campus expansion, with full operations slated to begin in early 2027. This adds to the partnership that has, to date, produced more than 150 million doses of medicine for patients in the U.S. in vial and pre-filled syringe formats. Together, the companies offer one of the nation's largest sterile injectable manufacturing operations, they said in a news release. Commentary from Resilience and Lilly officials. William S. Marth, president and CEO of Resilience, said: "We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio. Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Edgardo Hernandez, Lilly's EVP and president, Manufacturing Operations, said: "As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today's announcement highlights Resilience's role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments."
Lilly, Resilience to invest $750M in Ohio manufacturing. The expansion will add KwikPen device production and create at least 400 high-skilled jobs in the Cincinnati region. July 30, 2026 Associate Editor Editor's Take: Lilly has made several high-profile investments in the U.S. in the past year. In January, it chose the Lehigh Valley in Pennsylvania for its next manufacturing site, and in May, the company announced an additional $4.5 billion investment across two of its Indiana sites. Resilience and Eli Lilly and Company will invest $750 million to expand Resilience's advanced manufacturing operations in the Cincinnati, Ohio region, adding production of Lilly's KwikPen injectable device for diabetes and obesity medicines. According to the partners, the addition of KwikPen production will create at least 400 new high-skilled jobs, bringing total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Site preparation for the campus expansion is underway, with full operations expected to commence in early 2027. "We are proud of what we have built together with Lilly and this new expansion as we scale production of complex medicines in Ohio," said William S. Marth, President and CEO of Resilience. "Our investment reflects our long-term commitment to building one of the largest and most advanced sterile injectable and device assembly and packaging operations in the United States, and demonstrates how trusted partnerships, operational excellence, and disciplined execution can strengthen America's medicine supply." Edgardo Hernandez, Lilly's EVP and President, Manufacturing Operations, added, "As demand for our medicines continues to increase, scaling complex manufacturing programs requires proven technical capability, an uncompromising commitment to quality, and the ability to deliver consistently over time. Today's announcement highlights Resilience's role as a strong partner to Lilly in strengthening domestic supply of high-demand treatments." The multi-year manufacturing partnership between Lilly and Resilience has already produced more than 150 million doses of medicines for patients in the United States in vial and pre-filled syringe formats. Together, the companies have established one of the nation's largest sterile injectable manufacturing operations.